Multiple Sclerosis (MS) is a chronic and disabling disease characterized by demyelination of the central nervous system, which can lead to physical and cognitive impairment. The literature on MS cost-of-illness shows that (i) cost per patient is rather high; (ii) informal care and loss of productivity are the major cost components; (iii) health care costs have been showing a steady increase, mostly due to high costs of immunomodulator drugs launched into the market in the last fifteen years.
The objective of this research is to estimate health resources consumption and costs of patients suffering from MS in Piedmont Region relying on administrative databases, that include information on drugs, outpatient and inpatient services consumed and covered by the Regional Government to patients affected by MS.
Databases show (i) in 2008 a number of 109.9 patients per 100,000 population, (ii) a cost per patient of €6,103, with a 67% drugs incidence, (iii) a huge and significant decrease in costs from the younger to the elderly population, (iv) a small but statistically significant impact of co-morbidities on unit costs, and (v) a very costly proximity to death.
Despite its limitations — e.g. database incompleteness, which did not allow us covering all health care services — this study shows that resource use and cost analysis may rely on administrative databases, thus avoiding (or integrating) prospective studies, which may be long and costly.
This is a preview of subscription content, access via your institution.
Compston A, Coles A. Multiple sclerosis. Lancet 2001; 359: 1221–31
Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700–22
Patti F, Amato MP, Trojano M, et al. The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. Neurol Sci 2011; 32: 1035–41
Pugliatti M, Sotgiu S, Solinas G, et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001; 103: 20–6
Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6: 1–73
Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg 2010; 1125: 365–85
Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7: S45–54
Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249: 152–63
Berto P, Amato MP, Bellantonio P, et al. The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. Neurol Sci 2011; 32: 1035–41
Gori F. Il costo del paziente affetto da sclerosi multipla: l’esperienza di un Centro Specialistico nel Nord Italia. Giornale Italiano di Health Technologoy Assessment 2011; 4: 41–80
Pugliatti M, Sobocki P, Beghi E, et al. Cost of disorders of the brain in Italy. Neurol Sci 2008; 29; 99–107
Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy 2009; 29: 138–53
Gandhi SK, Salmon JW, Kong SX, et al. Administrative databases and outcomes assessment: an overview of issues and potential utility. J Manag Care Pharm 1999; 5: 215–22
Ministero Economia e Finanze. Relazione Generale sulla Situazione Economica del Paese, 2011
Seshamani M, Gray AM. A longitudinal study of the effects of age and time to death on hospital costs. J Health Econ 2004; 23: 217–35
About this article
Cite this article
Roggeri, D.P., Roggeri, A. & Jommi, C. Uso di database amministrativi per la rilevazione di consumo di risorse e spesa per pazienti affetti da sclerosi multipla nella Regione Piemonte. Pharmacoeconomics-Ital-Res-Articles 14, 79–89 (2012). https://doi.org/10.1007/BF03337456